Autopsy report · NCT03898661

Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures

“unexpected serious adverse event”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

University Hospital, Ghent

Sponsor type

University, hospital or other

Conditions

Stricture; Esophageal Stricture; Anastomotic; Collagenosis

Interventions

Collagenase histiolyticum

Participants

2

Sites

1

Countries

Belgium

Trials that died the same way

• Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes
  “Unexpected non-serious adverse events” (95% match in meaning)
• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (83% match in meaning)
• Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery
  “Adverse Event” (81% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (78% match in meaning)
• "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.
  “Suspicion of adverse events” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.